Key data catalysts for the industry’s small players

In a turbulent biotech market where positive news is often not rewarded, smaller companies hoping to avoid an even worse outcome this quarter are Intercept and Akero, which both have readouts in the notoriously tricky area of Nash. Elsewhere, Kymera hopes for no further trouble for its novel atopic dermatitis project, while Zealand wants to challenge Takeda with short bowel syndrome data.